Differential Proteomics and BIOARRAY Therapeutics join VDC

BIOARRAY Therapeutics, Inc. is developing a series of novel diagnostic tests based on gene expression technology. These new tests will detect breast cancer at its earliest stages and will help to predict the best therapy for each individual patient. BIOARRAY was...

NobleGen Biosciences joins VDC

With a proof of concept in hand, startup NobleGen Biosciences is setting up at the VDC to develop and commercialize a single-molecule sequencing technology that uses arrays of solid-state nanopores and optical detection. The method comes from the lab of Amit Meller at...

4s3 Bioscience joins VDC

Susan Windham-Bannister, Massachusetts Life Sciences Center, and Dustin Armstrong, 4s3 Bioscience 4s3 Bioscience, Inc., an early-stage Massachusetts biotherapeutics company, is moving to the Venture Development Center, its first formal location. The company was...

Welcome Novophage Therapeutics!

Elects to launch in Massachusetts A group of up-and-comers backed by biotech veterans in the Boston area is moving to the VDC. Their startup is called Novophage Therapeutics which plans to make engineered viruses that may help combat the growing problem of resistance...